Patent ID: 7858300
Filing Date: 2010-12-28
Classification: C12Q

Abstract:
1. A method of predicting the responsiveness of a human follicular CD20 positive non-Hodgkin's lymphoma (NHL) patient to treatment with rituximab comprising: a) determining the identity of an amino acid residue at position 158 of the mature FcγRIIIa receptor of said human follicular CD20 positive non-Hodgkin's lymphoma (NHL) patient comprising obtaining a biological sample from a human follicular CD20 positive NHL patient and isolating and sequencing FcγRIIIa receptor polypeptides, or portions thereof containing an amino acid residue at position 158 of the mature form of the FcγRIIIa receptor from said biological sample to determine the amino acid residue at position 158 of said FcγRIIIa receptor polypeptides, or contacting antibody reagents specific for each allele of the FcγRIIIa receptor with said biological sample to determine the amino acid residue at position 158 present of said FcγRIIIa receptor; and b) identifying the amino acid residue at position 158 of the mature FcγRIIIa receptor as a valine (V) or phenylalanine (F), the presence of a homozygous (V/V) at position 158 of the FcγRIIIa receptor polypeptide being predictive of better responsiveness of said patient to treatment of follicular CD20 positive NHL with rituximab and the presence of a heterozygous (F/V) or a homozygous (F/F) at position 158 being predictive of a lower responsiveness of said patient to the treatment of follicular CD20 positive NHL with rituximab.